Biote Corp. Class A Common Stock (BTMD) — 分析摘要
Biote Corp. Class A Common Stock（BTMD）的市值为32.69百万美元，最近一年的营收同比增长了-2.5%。净利润率为14.1%。当前市盈率为5.6倍。
核心要点
- 营收同比变化-2.5%
- 净利润率14.1%
- 市盈率5.6倍
与MEDICINAL CHEMICALS & BOTANICAL PRODUCTS板块的其他公司相比，BTMD的营收增长为-2.5%，市盈率为5.6倍。
Biote Corp. Class A Common Stock (BTMD)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
Debt/EBITDA 为 6.5x — 高杠杆，存在再融资风险
股东权益为负，可能意味着资产负债表承压。
净利润较上一期下降 78.3%。
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
行业
MEDICINAL CHEMICALS & BOTANICAL PRODUCTS
员工人数
223
总部
IRVING, TX
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。